Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · November 02, 2022

Temozolomide vs Temozolomide Plus Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
J. Clin. Oncol 2022 Oct 19;[EPub Ahead of Print], PL Kunz, NT Graham, PJ Catalano, HS Nimeiri, GA Fisher, TA Longacre, CJ Suarez, BA Martin, JC Yao, MH Kulke, AE Hendifar, JC Shanks, MH Shah, MM Zalupski, EL Schmulbach, DL Reidy-Lagunes, JR Strosberg, PJ O'Dwyer, AB Benson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading